Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  vinblastine sulfate
Find trials that include:  Any drugs shown
Results 1-6 of 6 for your search:
Start Over
Surgery Alone, Surgery With Cyclophosphamide, Vinblastine, and Prednisolone (CVP), or CVP Alone in Treating Young Patients With Stage IA or Stage IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Phase: Phase IV
Type: Treatment
Age: 17 and under
Trial IDs: CDR0000667369, NCI-2014-02026, EU-21011, EUDRACT-2007-004092-19, EURONET-PHL-LP1, NCT01088750
Combination Chemotherapy with or without Radiation Therapy in Treating Young Patients with Favorable-Risk Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: HOD08, NCI-2009-01138, NCT00846742
Response-Based Therapy Assessed by PET Scan in Treating Patients with Stage I or Stage II Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 to 60
Trial IDs: CALGB 50801, NCI-2011-02034, CDR0000669076, NCT01118026
Combination Chemotherapy and Brentuximab Vedotin in Treating Patients with Stage I-II Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 60
Trial IDs: LCCC 1115, NCI-2013-00975, 12-0303, NCT01578967
Risk-Adapted Therapy in Treating Young Children with Brain Tumors
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 3 at diagnosis
Trial IDs: SJYC07, NCI-2011-01193, SJCRH-SJYC07, NCT00602667
Brentuximab Vedotin, Combination Chemotherapy, and Radiation Therapy in Treating Patients with Newly Diagnosed, Early Stage, Unfavorable-Risk Hodgkin Lymphoma
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 to 60
Trial IDs: 13-034, NCI-2013-01144, NCT01868451
Start Over